Highlights
- These medications can quietly affect your contraception. Ozempic, Wegovy, and Mounjaro can all reduce the reliability of oral contraceptives, particularly during dose increases. This matters whether or not you are trying to conceive.
- Fertility often improves, sometimes unexpectedly. Weight loss and improved insulin sensitivity can restore ovulation, which is why unplanned pregnancies on GLP-1s have become common enough to have a name.
- Muscle and bone are part of the conversation. Rapid weight loss without adequate protein and resistance training can affect muscle and bone density, a risk that rises further for women already navigating menopause.
- This is not a treatment to start without supervision. What works safely alongside your hormones, your fertility plans, and your existing health profile is a clinical decision, not a social media protocol.
Everywhere you look, someone has an opinion about Ozempic, Mounjaro, and Wegovy. A friend’s results. A headline about side effects. A celebrity transformation. What is much harder to find is a straightforward, clinical answer to the question that actually matters: what does this mean for my body, specifically?
Most of the content circulating about these medications is written to sell them or to frighten you away from them. Very little of it is written to simply inform you.
At Menovivre, we prescribe GLP-1 medications as part of a supervised, individualised programme, never in isolation and never without a full assessment of your hormonal and reproductive picture first. This article sets out what the evidence actually shows for women specifically: the fertility question, the contraception question, the hormone question, and who should think twice.
Quick Answer
Ozempic (semaglutide) and Mounjaro (tirzepatide) are GLP-1 receptor agonists that support weight loss by slowing digestion, reducing appetite, and improving insulin sensitivity. For women specifically, three things matter most before starting: both medications can reduce the effectiveness of oral contraceptives, particularly during dose escalation, so backup contraception is recommended. Weight loss and improved insulin sensitivity can restore ovulation, sometimes unexpectedly, which is why unplanned pregnancies have become common enough to be widely reported. And rapid weight loss without sufficient protein intake and resistance training can affect muscle and bone density. These medications can be safe and effective for many women, but the decision should be made with a clinician who understands your full hormonal and reproductive picture, not in isolation.
What Ozempic, Mounjaro and Wegovy Actually Do
Ozempic and Wegovy are both brand names for the same molecule, semaglutide, prescribed at different doses for different purposes: Ozempic for type 2 diabetes, Wegovy specifically for weight management. Mounjaro (tirzepatide) is a separate molecule that acts on a second pathway, GIP, alongside GLP-1, which is part of why it tends to produce slightly greater average weight loss.
All three work by slowing gastric emptying, increasing feelings of fullness, reducing appetite, and improving how the body responds to insulin. Mounjaro is also sold as Zepbound specifically for weight management, the same pairing relationship that exists between Ozempic and Wegovy.
All three are effective. Most users lose between 5 and 20 per cent of their body weight, and the metabolic improvements, particularly in insulin sensitivity, extend well beyond the number on the scale. None of that is in question. What is less discussed is what these changes mean specifically for women’s hormonal and reproductive health.
The Contraception Conversation Nobody Has Before Prescribing
This is the one that catches the most women off guard. GLP-1 medications slow gastric emptying, which can affect how oral medications are absorbed, including the contraceptive pill. Mounjaro’s prescribing information specifically warns that it may reduce the effectiveness of oral hormonal contraceptives, particularly during dose escalation, when gastrointestinal slowing is most pronounced. Wegovy shares the same active ingredient as Ozempic, so the same general caution around timing and dose increases applies.
This is precisely why regulators have updated guidance recommending backup, non-oral contraception, such as a barrier method or a long-acting reversible method, particularly in the weeks around starting or increasing your dose. If you are not currently trying to conceive and you rely on the pill, this is a conversation to have before you start, not after.
Fertility: The Side Effect Nobody Warned You About
Here is something genuinely unexpected: for many women, fertility improves on these medications, sometimes considerably.
Excess weight and insulin resistance can suppress ovulation, particularly in women with PCOS. As GLP-1 medications improve insulin resistance and reduce hyperandrogenism, ovulation can become more regular, sometimes after years of irregular or absent cycles. The combination of restored ovulation and reduced contraceptive reliability has led to enough unplanned pregnancies that the phenomenon now has an informal name in clinical circles.
If pregnancy is not your intention right now, this is worth taking seriously. If pregnancy is something you are hoping for, this is worth discussing with your clinician as a potential and genuinely positive development, not an accident to be managed quietly.
If You Are Trying to Conceive, or Become Pregnant Unexpectedly
GLP-1 medications are not recommended during pregnancy. The current precautionary guidance is to stop semaglutide at least two months before actively trying to conceive, allowing the medication to clear the body given its roughly one-week half-life. Tirzepatide is typically paused with a similar precautionary window.
If you discover you are pregnant while taking either medication, the guidance is to stop immediately and contact your obstetric or gynaecological clinician promptly. Early data from observational studies has not identified a clear pattern of increased risk, but the body of evidence remains limited, which is exactly why caution is advised rather than reassurance assumed.
Weighing It Up: Semaglutide and Tirzepatide
What Rapid Weight Loss Can Do to Muscle and Bone
This is a part of the conversation that deserves far more attention than it gets.
This applies across semaglutide and tirzepatide alike, whether prescribed as Ozempic, Wegovy, or Mounjaro. Rapid weight loss, regardless of the method, risks taking lean muscle and bone density along with fat if it is not actively protected against. Women are at a particularly elevated risk, because the menopausal transition independently accelerates bone loss as oestrogen declines. Combining a hormonal phase that is already reducing bone density with rapid weight loss that compounds it is a real and manageable risk, not a reason to avoid these medications outright.
The mitigation is well established: adequate protein intake, consistent resistance training, and monitoring of bone density and muscle mass alongside the weight loss itself. This is exactly why GLP-1 treatment works best as part of a supervised programme rather than a prescription handed over without a plan attached.
Who Should Think Carefully Before Starting
GLP-1 medications are not appropriate for everyone, and a thorough assessment should rule out the following before treatment begins:
- A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
- A history of pancreatitis
- Active gastroparesis or significant gastrointestinal motility disorders
- Pregnancy, or active plans to conceive within the next few months
- Gallbladder disease that has not been assessed
A full medical history, alongside relevant blood work, should always precede a prescription. If a clinician offers you a GLP-1 without asking about any of the above, that is a signal to ask more questions, not fewer.
Can You Combine a GLP-1 With HRT?
In most cases, yes, and for many women in midlife, the combination addresses two different dimensions of the same picture. HRT addresses the hormonal symptoms and long-term health implications of menopause. A GLP-1 addresses metabolic and weight-related concerns that often intensify during the same transition.
The two are not in conflict, but they should be managed by the same clinical team, with visibility into both prescriptions, your full bone and metabolic picture, and a coordinated plan. This is precisely the kind of joined-up care that gets lost when weight loss medication is sourced separately from the rest of a woman’s hormonal care.
This Deserves a Proper Conversation, Not a Quick Prescription
GLP-1 medications, whether Ozempic, Wegovy, or Mounjaro, can be genuinely life-changing for the right person, in the right context, with the right support around them. They can also be mismanaged in ways that affect your fertility plans, your bone health, and your hormonal balance if they are prescribed without a full picture of who you are.
At Menovivre, our GLP-1 and Weight Management Package includes the metabolic testing, body composition monitoring, and clinical supervision that this category of medication genuinely requires. If you are considering Ozempic, Wegovy, or Mounjaro and want a clinician who will ask you the right questions first, you can request an appointment without a GP referral.
Frequently Asked Questions
Q1: Is Ozempic safe for women?
Q2. Does Ozempic affect fertility?
Q3. Can I combine a GLP-1 with HRT or contraception?
Q4. What are the most common side effects for women specifically?
Q5. Who should not take Ozempic, Wegovy, or Mounjaro?
Q6. How is Mounjaro different from Ozempic and Wegovy for women?
Q7. Will I lose muscle and bone, not just fat?
Q8. Do I need a referral to be seen at Menovivre?
